Cover Image
市場調查報告書

肝癌:開發平台分析

Liver Cancer - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 337045
出版日期 內容資訊 英文 1073 Pages
訂單完成後即時交付
價格
Back to Top
肝癌:開發平台分析 Liver Cancer - Pipeline Review, H1 2016
出版日期: 2016年06月22日 內容資訊: 英文 1073 Pages
簡介

肝癌是在肝臟發生的癌症。危險因素為,肝炎、肝硬化、肝臟的疤痕化,男性,出生時的體重輕等。症候有右腹部腫塊或疼痛、皮膚發黃。治療有化療、放射治療、手術等。

本報告提供肝癌的治療藥開發平台的現狀及最新更新的各開發階段比較分析、企業和研究機關開發中的治療藥、治療藥的評估、後期階段及中止的計劃相關資訊等最新的新聞和發表。

  • 簡介
  • 肝癌 概要
  • 治療藥的開發
  • 企業開發中的治療藥
  • 大學/機關研究中的治療藥
  • 開發中產品概況
  • 企業開發中的產品
  • 大學/機關研究中的產品
  • 開發治療藥的企業
  • 治療藥的評估
  • 藥物簡介
  • 最近的開發平台趨勢
  • 暫停中的計劃
  • 開發中止的產品
  • 產品開發的里程碑
  • 附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC7964IDB

Summary

Global Markets Direct's, 'Liver Cancer - Pipeline Review, H1 2016', provides an overview of the Liver Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Liver Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Liver Cancer and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Liver Cancer
  • The report reviews pipeline therapeutics for Liver Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Liver Cancer therapeutics and enlists all their major and minor projects
  • The report assesses Liver Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Liver Cancer

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Liver Cancer
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Liver Cancer pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
  • Introduction
  • Liver Cancer Overview
  • Therapeutics Development
  • Liver Cancer - Therapeutics under Development by Companies
  • Liver Cancer - Therapeutics under Investigation by Universities/Institutes
  • Liver Cancer - Pipeline Products Glance
  • Liver Cancer - Products under Development by Companies
  • Liver Cancer - Products under Investigation by Universities/Institutes
  • Liver Cancer - Companies Involved in Therapeutics Development
  • Liver Cancer - Therapeutics Assessment
  • Drug Profiles
  • Liver Cancer - Dormant Projects
  • Liver Cancer - Discontinued Products
  • Liver Cancer - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Liver Cancer, H1 2016
  • Number of Products under Development for Liver Cancer - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Development by Companies, H1 2016 (Contd..1)
  • Number of Products under Development by Companies, H1 2016 (Contd..2)
  • Number of Products under Development by Companies, H1 2016 (Contd..3)
  • Number of Products under Development by Companies, H1 2016 (Contd..4)
  • Number of Products under Development by Companies, H1 2016 (Contd..5)
  • Number of Products under Development by Companies, H1 2016 (Contd..6)
  • Number of Products under Development by Companies, H1 2016 (Contd..7)
  • Number of Products under Development by Companies, H1 2016 (Contd..8)
  • Number of Products under Development by Companies, H1 2016 (Contd..9)
  • Number of Products under Development by Companies, H1 2016 (Contd..10)
  • Number of Products under Development by Companies, H1 2016 (Contd..11)
  • Number of Products under Development by Companies, H1 2016 (Contd..12)
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..1)
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Products under Development by Companies, H1 2016 (Contd..2)
  • Products under Development by Companies, H1 2016 (Contd..3)
  • Products under Development by Companies, H1 2016 (Contd..4)
  • Products under Development by Companies, H1 2016 (Contd..5)
  • Products under Development by Companies, H1 2016 (Contd..6)
  • Products under Development by Companies, H1 2016 (Contd..7)
  • Products under Development by Companies, H1 2016 (Contd..8)
  • Products under Development by Companies, H1 2016 (Contd..9)
  • Products under Development by Companies, H1 2016 (Contd..10)
  • Products under Development by Companies, H1 2016 (Contd..11)
  • Products under Development by Companies, H1 2016 (Contd..12)
  • Products under Development by Companies, H1 2016 (Contd..13)
  • Products under Development by Companies, H1 2016 (Contd..14)
  • Products under Development by Companies, H1 2016 (Contd..15)
  • Products under Development by Companies, H1 2016 (Contd..16)
  • Products under Development by Companies, H1 2016 (Contd..17)
  • Products under Development by Companies, H1 2016 (Contd..18)
  • Products under Investigation by Universities/Institutes, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016 (Contd..1)
  • Products under Investigation by Universities/Institutes, H1 2016 (Contd..2)
  • Liver Cancer - Pipeline by 4SC AG, H1 2016
  • Liver Cancer - Pipeline by AB Science SA, H1 2016
  • Liver Cancer - Pipeline by Acceleron Pharma, Inc., H1 2016
  • Liver Cancer - Pipeline by ACROVIS Pharma AG, H1 2016
  • Liver Cancer - Pipeline by Adaptimmune Therapeutics Plc, H1 2016
  • Liver Cancer - Pipeline by Aduro BioTech, Inc., H1 2016
  • Liver Cancer - Pipeline by Advanced Accelerator Applications S.A., H1 2016
  • Liver Cancer - Pipeline by Advenchen Laboratories, LLC, H1 2016
  • Liver Cancer - Pipeline by Alfact Innovation, H1 2016
  • Liver Cancer - Pipeline by Alnylam Pharmaceuticals, Inc., H1 2016
  • Liver Cancer - Pipeline by American Gene Technologies International Inc., H1 2016
  • Liver Cancer - Pipeline by Amgen Inc., H1 2016
  • Liver Cancer - Pipeline by AndroScience Corporation, H1 2016
  • Liver Cancer - Pipeline by APAvadis Biotechnologies Srl, H1 2016
  • Liver Cancer - Pipeline by Arbutus Biopharma Corporation, H1 2016
  • Liver Cancer - Pipeline by ArQule, Inc., H1 2016
  • Liver Cancer - Pipeline by Array BioPharma Inc., H1 2016
  • Liver Cancer - Pipeline by Arrowhead Pharmaceuticals, Inc., H1 2016
  • Liver Cancer - Pipeline by Astex Pharmaceuticals, Inc., H1 2016
  • Liver Cancer - Pipeline by AstraZeneca Plc, H1 2016
  • Liver Cancer - Pipeline by AVEO Pharmaceuticals, Inc., H1 2016
  • Liver Cancer - Pipeline by Bayer AG, H1 2016
  • Liver Cancer - Pipeline by Beijing Kawin Technology Share-Holding Co., Ltd., H1 2016
  • Liver Cancer - Pipeline by Betta Pharmaceuticals Co. Ltd., H1 2016
  • Liver Cancer - Pipeline by Bio-Cancer Treatment International Limited, H1 2016
  • Liver Cancer - Pipeline by BioCancell Ltd, H1 2016
  • Liver Cancer - Pipeline by Biogazelle, H1 2016
  • Liver Cancer - Pipeline by Biomics Biotechnologies Co., Ltd., H1 2016
  • Liver Cancer - Pipeline by Bioneer Corporation, H1 2016
  • Liver Cancer - Pipeline by BioStar Pharmaceuticals, Inc., H1 2016
  • Liver Cancer - Pipeline by Blueprint Medicines Corporation, H1 2016
  • Liver Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2016
  • Liver Cancer - Pipeline by Boston Biomedical, Inc., H1 2016
  • Liver Cancer - Pipeline by Can-Fite BioPharma Ltd., H1 2016
  • Liver Cancer - Pipeline by CASI Pharmaceuticals Inc., H1 2016
  • Liver Cancer - Pipeline by CCRP Therapeutics GmbH, H1 2016
  • Liver Cancer - Pipeline by Celgene Corporation, H1 2016
  • Liver Cancer - Pipeline by Celldex Therapeutics, Inc., H1 2016
  • Liver Cancer - Pipeline by Celprogen, Inc., H1 2016
  • Liver Cancer - Pipeline by Celsion Corporation, H1 2016
  • Liver Cancer - Pipeline by China Medical System Holdings Limited, H1 2016
  • Liver Cancer - Pipeline by Chiome Bioscience, Inc., H1 2016
  • Liver Cancer - Pipeline by Chipscreen Biosciences Ltd, H1 2016
  • Liver Cancer - Pipeline by Chroma Therapeutics Limited, H1 2016
  • Liver Cancer - Pipeline by CohBar, Inc., H1 2016
  • Liver Cancer - Pipeline by CytRx Corporation, H1 2016
  • Liver Cancer - Pipeline by CZ BioMed Corp, H1 2016
  • Liver Cancer - Pipeline by Daiichi Sankyo Company, Limited, H1 2016
  • Liver Cancer - Pipeline by Delcath Systems, Inc., H1 2016
  • Liver Cancer - Pipeline by Dicerna Pharmaceuticals, Inc., H1 2016
  • Liver Cancer - Pipeline by Digna Biotech, S.L., H1 2016
  • Liver Cancer - Pipeline by Double Bond Pharmaceutical International AB, H1 2016
  • Liver Cancer - Pipeline by Eisai Co., Ltd., H1 2016
  • Liver Cancer - Pipeline by Eli Lilly and Company, H1 2016
  • Liver Cancer - Pipeline by Endocyte, Inc., H1 2016
  • Liver Cancer - Pipeline by eTheRNA Immunotherapies NV, H1 2016
  • Liver Cancer - Pipeline by Eureka Therapeutics, Inc., H1 2016
  • Liver Cancer - Pipeline by Exelixis, Inc., H1 2016
  • Liver Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016
  • Liver Cancer - Pipeline by Genelux Corporation, H1 2016
  • Liver Cancer - Pipeline by Genoscience Pharma, H1 2016
  • Liver Cancer - Pipeline by Genosco, H1 2016
  • Liver Cancer - Pipeline by GenSpera, Inc., H1 2016
  • Liver Cancer - Pipeline by GlaxoSmithKline Plc, H1 2016
  • Liver Cancer - Pipeline by Golden Biotechnology Corp., H1 2016
  • Liver Cancer - Pipeline by Green Cross Cell Corporation, H1 2016
  • Liver Cancer - Pipeline by H3 Biomedicine Inc., H1 2016
  • Liver Cancer - Pipeline by HanAll Biopharma Co., Ltd., H1 2016
  • Liver Cancer - Pipeline by HEC Pharm Co., Ltd., H1 2016
  • Liver Cancer - Pipeline by HitGen LTD, H1 2016
  • Liver Cancer - Pipeline by Horizon Pharma Plc, H1 2016
  • Liver Cancer - Pipeline by Huperion Sarl, H1 2016
  • Liver Cancer - Pipeline by Immunicum AB, H1 2016
  • Liver Cancer - Pipeline by Immunitor, Inc., H1 2016
  • Liver Cancer - Pipeline by Immunomedics, Inc., H1 2016
  • Liver Cancer - Pipeline by Immunovative Therapies, Ltd., H1 2016
  • Liver Cancer - Pipeline by IMPACT Therapeutics, Inc., H1 2016
  • Liver Cancer - Pipeline by In-Cell-Art S.A.S., H1 2016
  • Liver Cancer - Pipeline by Incanthera Ltd., H1 2016
  • Liver Cancer - Pipeline by Incuron, LLC, H1 2016
  • Liver Cancer - Pipeline by InteRNA Technologies B.V., H1 2016
  • Liver Cancer - Pipeline by Jasco Pharmaceuticals, LLC., H1 2016
  • Liver Cancer - Pipeline by Jenrin Discovery, Inc., H1 2016
  • Liver Cancer - Pipeline by Johnson & Johnson, H1 2016
  • Liver Cancer - Pipeline by JW Pharmaceutical Corporation, H1 2016
  • Liver Cancer - Pipeline by KAHR medical Ltd., H1 2016
  • Liver Cancer - Pipeline by Karcinolys SAS, H1 2016
  • Liver Cancer - Pipeline by Keystone Nano, Inc., H1 2016
  • Liver Cancer - Pipeline by Kite Pharma, Inc., H1 2016
  • Liver Cancer - Pipeline by Komipharm International Co., Ltd., H1 2016
  • Liver Cancer - Pipeline by Kowa Company, Ltd., H1 2016
  • Liver Cancer - Pipeline by Les Laboratoires Servier SAS, H1 2016
  • Liver Cancer - Pipeline by Ligand Pharmaceuticals, Inc., H1 2016
  • Liver Cancer - Pipeline by Lixte Biotechnology Holdings, Inc., H1 2016
  • Liver Cancer - Pipeline by Lytix Biopharma AS, H1 2016
  • Liver Cancer - Pipeline by MaxCyte, Inc., H1 2016
  • Liver Cancer - Pipeline by MedImmune, LLC, H1 2016
  • Liver Cancer - Pipeline by Medivation, Inc., H1 2016
  • Liver Cancer - Pipeline by Medivir AB, H1 2016
  • Liver Cancer - Pipeline by Merck & Co., Inc., H1 2016
  • Liver Cancer - Pipeline by Merck KGaA, H1 2016
  • Liver Cancer - Pipeline by Merrimack Pharmaceuticals, Inc., H1 2016
  • Liver Cancer - Pipeline by Midatech Pharma Plc, H1 2016
  • Liver Cancer - Pipeline by Millennium Pharmaceuticals, Inc., H1 2016
  • Liver Cancer - Pipeline by Mirna Therapeutics, Inc., H1 2016
  • Liver Cancer - Pipeline by Molecular Partners AG, H1 2016
  • Liver Cancer - Pipeline by MolMed S.p.A., H1 2016
  • Liver Cancer - Pipeline by MultiCell Technologies, Inc., H1 2016
  • Liver Cancer - Pipeline by Nimbus Therapeutics, LLC, H1 2016
  • Liver Cancer - Pipeline by NormOxys, Inc., H1 2016
  • Liver Cancer - Pipeline by Northwest Biotherapeutics, Inc., H1 2016
  • Liver Cancer - Pipeline by Novartis AG, H1 2016
  • Liver Cancer - Pipeline by NovaTarg Therapeutics, Inc, H1 2016
  • Liver Cancer - Pipeline by Nymox Pharmaceutical Corporation, H1 2016
  • Liver Cancer - Pipeline by Omeros Corporation, H1 2016
  • Liver Cancer - Pipeline by Omnitura Therapeutics Inc., H1 2016
  • Liver Cancer - Pipeline by Oncolys BioPharma Inc., H1 2016
  • Liver Cancer - Pipeline by OncoMed Pharmaceuticals, Inc., H1 2016
  • Liver Cancer - Pipeline by OncoTherapy Science, Inc., H1 2016
  • Liver Cancer - Pipeline by Oneness Biotech Co., Ltd., H1 2016
  • Liver Cancer - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016
  • Liver Cancer - Pipeline by Onxeo SA, H1 2016
  • Liver Cancer - Pipeline by OPKO Health, Inc., H1 2016
  • Liver Cancer - Pipeline by Oribase Pharma, H1 2016
  • Liver Cancer - Pipeline by Otsuka Holdings Co., Ltd., H1 2016
  • Liver Cancer - Pipeline by Panacea Pharmaceuticals, Inc., H1 2016
  • Liver Cancer - Pipeline by Peptinov SAS, H1 2016
  • Liver Cancer - Pipeline by Pfizer Inc., H1 2016
  • Liver Cancer - Pipeline by Pharma Mar, S.A., H1 2016
  • Liver Cancer - Pipeline by PharmAbcine, Inc., H1 2016
  • Liver Cancer - Pipeline by PharmaEssentia Corporation, H1 2016
  • Liver Cancer - Pipeline by Phosplatin Therapeutics LLC, H1 2016
  • Liver Cancer - Pipeline by Polaris Pharmaceuticals, Inc., H1 2016
  • Liver Cancer - Pipeline by Progen Pharmaceuticals Limited, H1 2016
  • Liver Cancer - Pipeline by ProMetic Life Sciences Inc., H1 2016
  • Liver Cancer - Pipeline by Provecs Medical GmbH, H1 2016
  • Liver Cancer - Pipeline by Provectus Biopharmaceuticals, Inc., H1 2016
  • Liver Cancer - Pipeline by Quimatryx, S.L., H1 2016
  • Liver Cancer - Pipeline by Raptor Pharmaceutical Corp., H1 2016
  • Liver Cancer - Pipeline by RedHill Biopharma Ltd., H1 2016
  • Liver Cancer - Pipeline by Regen BioPharma, Inc., H1 2016
  • Liver Cancer - Pipeline by Regulus Therapeutics Inc., H1 2016
  • Liver Cancer - Pipeline by Rigontec GmbH, H1 2016
  • Liver Cancer - Pipeline by Saronic Biotechnology, Inc., H1 2016
  • Liver Cancer - Pipeline by Savoy Pharmaceuticals, Inc., H1 2016
  • Liver Cancer - Pipeline by Shenogen Pharma Group Ltd., H1 2016
  • Liver Cancer - Pipeline by Shenzen SiBiono GeneTech Co., Ltd., H1 2016
  • Liver Cancer - Pipeline by Silence Therapeutics Plc, H1 2016
  • Liver Cancer - Pipeline by Sillajen Biotherapeutics, H1 2016
  • Liver Cancer - Pipeline by Simcere Pharmaceutical Group, H1 2016
  • Liver Cancer - Pipeline by Synovo GmbH, H1 2016
  • Liver Cancer - Pipeline by Taiwan Liposome Company, Ltd., H1 2016
  • Liver Cancer - Pipeline by Tara Immuno-Oncology Therapeutics LLC, H1 2016
  • Liver Cancer - Pipeline by Targetome, H1 2016
  • Liver Cancer - Pipeline by Therapure Biopharma Inc., H1 2016
  • Liver Cancer - Pipeline by Theravectys SA, H1 2016
  • Liver Cancer - Pipeline by Tiziana Life Sciences Plc, H1 2016
  • Liver Cancer - Pipeline by Toko Pharmaceutical Industries Co., Ltd., H1 2016
  • Liver Cancer - Pipeline by TRACON Pharmaceuticals, Inc., H1 2016
  • Liver Cancer - Pipeline by Transgene Biotek Limited, H1 2016
  • Liver Cancer - Pipeline by Tumorend, LLC, H1 2016
  • Liver Cancer - Pipeline by UbiVac, LLC, H1 2016
  • Liver Cancer - Pipeline by VasGene Therapeutics, Inc., H1 2016
  • Liver Cancer - Pipeline by Vaxon Biotech, H1 2016
  • Liver Cancer - Pipeline by Vect-Horus S.A.S., H1 2016
  • Liver Cancer - Pipeline by Verlyx Pharma Inc., H1 2016
  • Liver Cancer - Pipeline by VG Life Sciences, Inc., H1 2016
  • Liver Cancer - Pipeline by Vicus Therapeutics, LLC, H1 2016
  • Liver Cancer - Pipeline by Virttu Biologics Limited, H1 2016
  • Liver Cancer - Pipeline by Vyriad, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Liver Cancer - Dormant Projects, H1 2016
  • Liver Cancer - Dormant Projects (Contd..1), H1 2016
  • Liver Cancer - Dormant Projects (Contd..2), H1 2016
  • Liver Cancer - Dormant Projects (Contd..3), H1 2016
  • Liver Cancer - Dormant Projects (Contd..4), H1 2016
  • Liver Cancer - Dormant Projects (Contd..5), H1 2016
  • Liver Cancer - Dormant Projects (Contd..6), H1 2016
  • Liver Cancer - Dormant Projects (Contd..7), H1 2016
  • Liver Cancer - Dormant Projects (Contd..8), H1 2016
  • Liver Cancer - Dormant Projects (Contd..9), H1 2016
  • Liver Cancer - Dormant Projects (Contd..10), H1 2016
  • Liver Cancer - Dormant Projects (Contd..11), H1 2016
  • Liver Cancer - Dormant Projects (Contd..12), H1 2016
  • Liver Cancer - Dormant Projects (Contd..13), H1 2016
  • Liver Cancer - Dormant Projects (Contd..14), H1 2016
  • Liver Cancer - Dormant Projects (Contd..15), H1 2016
  • Liver Cancer - Dormant Projects (Contd..16), H1 2016
  • Liver Cancer - Dormant Projects (Contd..17), H1 2016
  • Liver Cancer - Discontinued Products, H1 2016
  • Liver Cancer - Discontinued Products (Contd..1), H1 2016
  • Liver Cancer - Discontinued Products (Contd..2), H1 2016
  • Liver Cancer - Discontinued Products (Contd..3), H1 2016

List of Figures

  • Number of Products under Development for Liver Cancer, H1 2016
  • Number of Products under Development for Liver Cancer - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Top 10 Routes of Administration, H1 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2016
  • Number of Products by Top 10 Molecule Types, H1 2016
  • Number of Products by Stage and Top 10 Molecule Types, H1 2016
Back to Top